Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237351 | 0.88 | SLC6A9 (0.51) | SLC6A9ALDH1A1 | |
| SCHEMBL3240768 | 0.86 | SLC6A9 (0.58) | SLC6A9ALDH1A1KMT2A | |
| SCHEMBL3237485 | 0.84 | SLC6A9 (0.48) | SLC6A9ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL13303916 | 0.83 | SLC6A9 (0.47) | TAS1R3TAS1R1SLC6A9ALDH1A1KMT2A | |
| SCHEMBL3233042 | 0.82 | SLC6A9 (0.52) | TAS1R3TAS1R1TAS1R2SLC6A9ALDH1A1 | |
| SCHEMBL3236972 | 0.82 | SLC6A9 (0.47) | SLC6A9 | |
| SCHEMBL3240614 | 0.81 | SLC6A9 (0.56) | SLC6A9 | |
| SCHEMBL8264425 | 0.80 | SLC6A9 (0.50) | SLC6A9ALDH1A1KMT2A | |
| SCHEMBL3239398 | 0.80 | SLC6A9 (0.55) | SLC6A9 | |
| SCHEMBL3237710 | 0.80 | ALDH1A1 (0.42) | SLC6A9ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | TAS1R3 3167/4885TAS1R1 2565/4885TAS1R2 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.